Salestools LogoSalestools
Salestools AI-agenter
Løsninger
Ressourcer
Virksomhed
Priser
Salestools Logo

Salestools

#1 AI-agent til salgsteams og Go-to-Market-teams. Sælg mere, hurtigere, med mindre indsats.

Produkt

  • AI-salgsagenter
  • Intent-data
  • Teknologidata
  • Besøgssporing
  • Co-Pilot
  • Socialt salg

Løsninger

  • Kundeservice
  • E-handel
  • SaaS
  • Enterprise
  • Lille virksomhed

Ressourcer

  • Rapporten
  • Dokumentation
  • API-reference
  • Hjælpecenter
  • Blog
  • Case-studier
  • Webinarer

Virksomhed

  • Om os
  • Karriere
  • Presse
  • Kontakt
  • Partnere

Vores lokationer

  • New York, HQ
  • Bukarest, AI-forskningslaboratorium
  • Zug, Schweiz

© 2025 Salestools. Alle rettigheder forbeholdes.

Datavilkår & sikkerhedPrivatlivspolitikServicevilkår
Alle systemer operationelle
Salestools LogoSalestools
Salestools AI-agenter
Løsninger
Ressourcer
Virksomhed
Priser
Back to The Report
Fundraising

Verily Life Sciences

Verily Life Sciences Raises $1B in Series D

2015
Founded
1500+
Employees
South San Francisco, CA
Updated January 12, 2022
2 min read

Quick Facts

Verily Life Sciences Raises $1B in Series D


Verily Life Sciences has successfully raised $1B in a Series D at a $6B valuation led by Temasek, Silver Lake, Ontario Teachers.


Company Overview


Verily Life Sciences is a HealthTech company headquartered in South San Francisco, CA, founded in 2015 with 1500+ employees.


Precision health and life sciences research


Fundraising Details


  • Amount Raised: $1B
  • Round Type: Series D
  • Valuation: $6B
  • Date: 2022-01-12
  • Investors: Temasek, Silver Lake, Ontario Teachers

About Verily Life Sciences


Precision health and life sciences research The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: South San Francisco, CA
  • Founded: 2015
  • Team Size: 1500+
  • Industry: HealthTech

What This Means


This funding round demonstrates strong investor confidence in Verily Life Sciences's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Verily Life Sciences's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $6B valuation marks an important milestone for Verily Life Sciences, positioning the company among notable players in the HealthTech industry.


Looking Ahead


With this new capital, Verily Life Sciences is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2022-01-12. For more information about Verily Life Sciences, visit their headquarters at South San Francisco, CA.

Topics

Fundraising(2912)HealthTech(503)Series DVerily Life Sciences

About the Author

Fundraising News Team
Fundraising News Team
Tracking the latest funding rounds and investment news

Related Company Reports

Fundraising
Harvey AI

Harvey AI Raises $160 million in Series F

Harvey AI, a AI Software company based in San Francisco CA, has raised $160 million in Series F at a $8 billion valuation led by Andreessen Horowitz.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•160 million
Fundraising
7AI

7AI Raises $130 million in Series A

7AI, a Cybersecurity company based in Boston MA, has raised $130 million in Series A at a $700 million valuation led by Index Ventures.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•130 million
Fundraising
TRIANA Biomedicines

TRIANA Biomedicines Raises $120 million in Series B

TRIANA Biomedicines, a Biotechnology company based in Lexington MA, has raised $120 million in Series B at a Undisclosed led by Ascenta Capital.

Market Intelligence Team
Market Intelligence Team
Dec 3, 2025
0 min read•120 million